Healey Center Platform Trial for ALS
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. In this trial, multiple drugs (Regimen A – Zilucoplan; Regimen B – Verdiperstat; Regimen C – CNM-Au8) for ALS will be tested simultaneously or sequentially. Each drug will be tested in a regimen. Each regimen consists of a placebo-controlled trial, meaning that the active drug and matching placebo will be tested in each regimen.
Related News: U-M ALS Center of Excellence Participates in National Clinical Drug Trial
Safety Study of Oral Edaravone Administered in Subjects With ALS
The objective of this study is to evaluate the long-term safety and tolerability of oral edaravone in subjects with Amyotrophic Lateral Sclerosis (ALS) over 24 and 48 weeks.
An up-to-date listing of our studies can be found here
Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS (REFALS)
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (CENTAUR)
A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS) (FORTITUDE-ALS)
Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (Mexiletine-2)
Clinical Trial of Ezogabine (Retigabine) in ALS Subjects
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year (VITALITY-ALS)
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
For questions on clinical trials at the University of Michigan, please email Jayna Duell at email@example.com